Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$29.50
+1.5%
$28.13
$23.23
$42.29
$947.89M0.63431,521 shs174,596 shs
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$23.87
+2.2%
$20.03
$16.16
$26.55
$966.60M0.62195,395 shs151,301 shs
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
$21.98
+1.3%
$24.80
$6.20
$29.27
$242.73M0.169,433 shs13,585 shs
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$8.48
-0.7%
$8.33
$6.50
$18.98
$898.22M0.88837,096 shs432,917 shs
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
-2.45%+7.47%+8.75%-6.17%-12.68%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
-5.04%+20.47%+30.43%-7.26%+28.28%
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
-6.14%-1.45%-11.21%+8.50%+2,169,999,900.00%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-1.15%+7.90%+11.60%-32.67%-49.94%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
3.8446 of 5 stars
3.40.00.03.02.60.82.5
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
3.6646 of 5 stars
0.83.02.51.13.43.32.5
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
3.6245 of 5 stars
4.60.00.00.02.12.51.3
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
2.9392 of 5 stars
4.51.00.00.01.84.20.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
2.80
Moderate Buy$43.8048.47% Upside
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
1.50
Reduce$20.00-16.20% Downside
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
3.13
Buy$44.43102.13% Upside
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
2.91
Moderate Buy$25.67202.57% Upside

Current Analyst Ratings Breakdown

Latest PVLA, PAHC, COLL, and RCUS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.00
5/9/2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$24.00 ➝ $22.00
5/8/2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $21.00
5/8/2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.00
5/7/2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$33.00
5/7/2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$29.00 ➝ $26.00
4/30/2025
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
4/23/2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$29.00 ➝ $14.00
4/15/2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$20.00
4/9/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
4/9/2025
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$50.00
(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$664.28M1.43$10.69 per share2.76$5.99 per share4.92
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$1.11B0.87$2.20 per share10.87$6.09 per share3.92
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
$42.81M5.67N/AN/A$21.66 per share1.01
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$141M6.37N/AN/A$6.17 per share1.37
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$48.15M$1.2212.724.90N/A14.78%104.67%18.38%N/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$2.42M$0.7849.7211.360.451.75%25.35%6.21%N/A
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
-$24.54M-$12.10N/AN/AN/AN/A-80.93%-59.55%5/15/2025 (Estimated)
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$307M-$4.19N/AN/AN/A-102.66%-45.59%-22.38%N/A

Latest PVLA, PAHC, COLL, and RCUS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
-$3.40-$0.74+$2.66-$0.74N/AN/A
5/8/2025Q1 2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.50$1.49-$0.01$0.07$174.96 million$177.76 million
5/7/2025Q3 2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$0.52$0.63+$0.11$0.51$352.41 million$347.80 million
5/6/2025Q1 2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$1.02-$1.14-$0.12-$1.14$38.61 million$28.00 million
2/27/2025Q4 2024
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.54$1.63+$0.09$0.36$179.68 million$181.95 million
2/25/2025Q4 2024
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$1.17-$1.03+$0.14-$1.03$29.38 million$36.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/AN/AN/AN/AN/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$0.482.01%N/A61.54%N/A
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
N/AN/AN/AN/AN/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
N/AN/AN/AN/AN/A

Latest PVLA, PAHC, COLL, and RCUS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
quarterly$0.122.52%6/4/20256/4/20256/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
3.43
0.97
0.88
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
2.99
3.20
1.37
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
N/A
4.82
4.82
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
0.08
5.24
5.24

Institutional Ownership

CompanyInstitutional Ownership
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
99.34%
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
40.11%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
92.89%
CompanyEmployeesShares OutstandingFree FloatOptionable
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
21032.13 million30.97 millionOptionable
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
1,86040.50 million20.22 millionOptionable
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
N/A11.04 million10.50 millionN/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
500105.89 million80.26 millionOptionable

Recent News About These Companies

FY2025 EPS Forecast for Arcus Biosciences Cut by Analyst
HC Wainwright Brokers Decrease Earnings Estimates for RCUS
Wedbush Predicts Arcus Biosciences' Q2 Earnings (NYSE:RCUS)
Q1 2025 Arcus Biosciences Inc Earnings Call

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Collegium Pharmaceutical stock logo

Collegium Pharmaceutical NASDAQ:COLL

$29.50 +0.43 (+1.48%)
As of 02:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$23.86 +0.51 (+2.16%)
As of 02:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Palvella Therapeutics stock logo

Palvella Therapeutics NASDAQ:PVLA

$21.98 +0.28 (+1.29%)
As of 02:26 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Arcus Biosciences stock logo

Arcus Biosciences NYSE:RCUS

$8.48 -0.06 (-0.67%)
As of 02:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.